We are thrilled to present to our community the launch of the product VETRANO® palbociclib, for our Oncology Line.

VETRANO® palbociclib is indicated for the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 (HER2-) negative, metastatic or locally advanced breast cancer.

VETRANO® palbociclib is available in the following dosages:
– 75 mg x 21 coated tablets
– 100 mg x 21 coated tablets
– 125 mg x 21 coated tablets

VETRANO® palbociclib joins the portfolio of products for the treatment of breast cancer, together with DIMERE® fulvestrant, IDELARA® letrozole y ANASTRADEX® anastrozol.

We invite you all to read the following material to learn more about the product!

Bioprofarma Bagó
Working in the present, thinking the future.